Anzor Pharmaceuticals Licenses Key Fibroblast Growth Factor Technology From New York University

FGF Technology Represents Major Breakthrough In Metabolic and Cancer Diseases
Anzor Pharmaceuticals [http://www.anzorpharma.com/], a leader in the development of targeted fibroblast growth factor (FGF) peptide therapy, today announced an exclusive worldwide license for FGF technology developed by Dr. Moos Mohammadi, Ph.D., the company's Chief Scientific Officer.

Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXe8vcqcPFnNQQ20Shtn9Os5Jbwz8wGL8dcXteSBptfFT6MQkZkxQhfbUissP-gB8qrhcl5VPvMNEGoQBNwdkga4K65eWUwVNhtWiG6rfBgmEKY22MqU4d3DFIrvzMggGmkkSBud_Q?key=IRDAcoZk7J2GNJep-4n0FYQM

The licensed FGF technology from NYU has shown promising results in preclinical studies, demonstrating significant potential for treating various metabolic and cancer-related conditions. Dr. Mohammadi's research has revealed the remarkable effects of FGF-based interventions in animal models of endocrine and metabolic diseases.

According to one study, Type 2 diabetes (T2D) is a major health and economic burden worldwide with sustained remission currently unachievable pharmacologically. In an obesity animal model [https://pubmed.ncbi.nlm.nih.gov/37167965/], an FGF-based peptide ligand produced marked weight loss over a 30-day period. The study demonstrates that icvFGF4 elicits a sustained antidiabetic effect in mice, and excites glucose-excited (GE) neurons while inhibiting glucose-inhibited (GI) neurons. This shows significant therapeutic potential for icvFGF4 in achieving sustained remission of T2D.

In a chronic kidney disease animal model [https://pubmed.ncbi.nlm.nih.gov/38299214/], an FGF peptide ligand significantly enhanced kidney function. Cardiovascular disease (CVD) is the major cause of death in chronic kidney disease and is associated with high circulating fibroblast growth factor (FGF)23 levels. In three murine models with high endogenous FGF23 and cardiomyopathy, data has indicated high endogenous iFGF23 is not just a mere biomarker but pathogenically deleterious in CKD and cardiomyopathy. By blocking FGF23 signaling with a natural proteolytic product of iFGF23, C-terminal FGF23, kidney, and cardiac histology can be alleviated.

These findings highlight the broad applicability of fibroblast growth factor-based therapy in addressing critical health issues.

"This license agreement represents a significant opportunity for Anzor to bring relief to millions of patients around the world," said Christopher Adams, CEO, of Anzor. "We are excited to advance our proprietary FGF peptides and conjugates in the treatment of obesity, chronic kidney disease, and skeletal disorders."

For more information about Anzor Pharmaceuticals, please visit www.anzorpharma.com [http://www.anzorpharma.com/].

About Anzor Pharmaceuticals

Anzor Pharmaceuticals is at the forefront of targeted fibroblast growth factor (FGF) therapies for cancer and metabolic disorders. The company's technology is based on proprietary FGF peptides and conjugates, with applications in obesity, chronic kidney disease, and skeletal disorders. Extensive research has demonstrated that FGF receptors are involved in several key pathways of disease.
Media Contact
Company Name: Anzor Pharmaceuticals
Contact Person: Chris Adams
Email: Send Email [http://www.universalpressrelease.com/?pr=anzor-pharmaceuticals-licenses-key-fibroblast-growth-factor-technology-from-new-york-university]
Phone: 617-957-9858
City: Boston
State: Massachusetts
Country: United States
Website: http://www.anzorpharma.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.